Starling Oncology, Inc. Interest Expense Nonoperating
Starling Oncology, Inc. (DFPH) reported Interest Expense Nonoperating of $1.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Starling Oncology, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $1.86M, a 0.59% decline year-over-year.
- Starling Oncology, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $1.93M, a 65.28% decline year-over-year.
- Starling Oncology, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $1.92M, a 64.04% increase year-over-year.
- Starling Oncology, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $1.92M, a 13.71% decline year-over-year.
- Starling Oncology, Inc. interest expense nonoperating for fiscal 2025 was $11.28M, a 50.43% increase from fiscal 2024.
- Starling Oncology, Inc. interest expense nonoperating for fiscal 2024 was $7.50M, a 10.61% increase from fiscal 2023.
- Starling Oncology, Inc. interest expense nonoperating for fiscal 2023 was $6.78M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.86M 10-Q · filed 2026-08-06 | $3.79M 10-Q · filed 2026-08-06 | $5.71M derived: sum of 3 quarters · filed 2026-08-06 | $7.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.93M 10-Q · filed 2026-05-07 | $3.85M derived: sum of 2 quarters · filed 2026-05-07 | $5.77M derived: sum of 3 quarters · filed 2026-05-07 | $7.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.84M derived: sum of 2 quarters · filed 2026-03-12 | $5.71M derived: sum of 3 quarters · filed 2026-08-06 | $11.28M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.92M 10-Q · filed 2025-11-13 | $3.79M derived: sum of 2 quarters · filed 2026-08-06 | $9.36M 10-Q · filed 2025-11-13 | $10.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.87M 10-Q · filed 2026-08-06 | $7.44M 10-Q · filed 2026-08-06 | $8.61M derived: sum of 3 quarters · filed 2026-08-06 | $10.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.57M 10-Q · filed 2026-05-07 | $6.74M derived: sum of 2 quarters · filed 2026-05-07 | $8.96M derived: sum of 3 quarters · filed 2026-05-07 | $11.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.39M derived: sum of 2 quarters · filed 2026-03-12 | $5.51M derived: sum of 3 quarters · filed 2026-03-12 | $7.50M 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.23M 10-Q · filed 2025-11-13 | $4.34M derived: sum of 2 quarters · filed 2025-11-13 | $6.33M 10-Q · filed 2025-11-13 | $8.27M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.12M 10-Q · filed 2025-08-13 | $4.10M 10-Q · filed 2025-08-13 | $6.04M derived: sum of 3 quarters · filed 2025-08-13 | $7.80M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.99M 10-Q · filed 2025-05-14 | $3.93M derived: sum of 2 quarters · filed 2025-05-14 | $5.68M derived: sum of 3 quarters · filed 2025-05-14 | $7.32M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $3.70M derived: sum of 2 quarters · filed 2025-03-26 | $5.33M derived: sum of 3 quarters · filed 2025-03-26 | $6.78M 10-K · filed 2025-03-26 |
| 2023-09-30 | $1.75M 10-Q · filed 2024-11-13 | $3.39M derived: sum of 2 quarters · filed 2024-11-13 | $4.84M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $1.64M 10-Q · filed 2024-08-13 | $3.08M 10-Q · filed 2024-08-13 |